NCT05644561 2026-04-17
Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
Clinical Trials
7 trialsNCT06909253 2026-04-17
MG-ARCADIA
AstraZeneca
Recruiting
NCT06312644 2026-04-16
Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy
Alexion Pharmaceuticals, Inc.
Recruiting
NCT07221838 2026-04-09
OCTAGON
Alexion Pharmaceuticals, Inc.
Phase 4 Recruiting
NCT06967480 2026-02-05
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Recruiting
NCT04201262 2025-10-14
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT03920293 2024-05-28
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Completed